Resumo

MEDINA-ORNELAS, Sevastián  e  GRANADOS-GARCIA, Martín. Thyroid cancer, redefining the radioiodine-refractoriness (RAIR). Gac. mex. oncol. [online]. 2021, vol.20, n.4, pp.148-157.  Epub 06-Dez-2021. ISSN 2565-005X.  https://doi.org/10.24875/j.gamo.21000058.

Differentiated thyroid cancer (DTC) maybe is the neoplasm with the best outcome; however, the development of metastases means a less favorable scenario, where the use of iodine-131 (I-131) represents the best therapeutic option; although a group of patients will not get a good response. It is important to know the multidisciplinary approach to this condition, since it produces the best results; but it is important to understand the phenomenon of radioiodine-refractoriness (RAIR); since there is currently a lot of controversy. Next are describe 5 categories of the RAIR, these classifications seek to obtain the greatest benefit from treatment with I-131.

Palavras-chave : Differentiated thyroid cancer; Radioiodine-refractoriness; Iodine-131.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )